Director at Artiva Biotherapeutics (ARTV) granted 27,500 stock options

Rhea-AI Filing Summary

Sorg Elaine K. reported acquisition or exercise transactions in this Form 4 filing.

Artiva Biotherapeutics director receives stock option grant

Artiva Biotherapeutics, Inc. director Elaine K. Sorg was granted a Director Stock Option covering 27,500 shares on February 18, 2026. The option has a grant price of $0.00 per share, reflecting a compensatory award rather than an open-market purchase.

According to the vesting terms, one-third of the 27,500 shares vested following the grant date. The remaining shares vest monthly over an additional two years following February 18, 2026, aligning the director’s compensation with longer-term company performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sorg Elaine K.

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$4.15	02/18/2026		A		27,500		(1)	02/17/2036	Common Stock	27,500	$0	27,500	D

Explanation of Responses:

1. One-third of the shares vested following the grant date, with the remaining shares vesting monthly over an additional two years following February 18, 2026.

	/s/ Andrew Cronauer, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Artiva Biotherapeutics (ARTV) report for Elaine K. Sorg?

Artiva Biotherapeutics reported that director Elaine K. Sorg received a Director Stock Option grant covering 27,500 shares on February 18, 2026. This was a compensatory option award, not an open-market share purchase, and is reported as an acquisition of derivative securities.

How many shares are covered by Elaine K. Sorg’s Artiva Biotherapeutics (ARTV) stock option?

The Director Stock Option awarded to Elaine K. Sorg covers 27,500 underlying shares of Artiva Biotherapeutics, Inc. This entire amount is reported as beneficially owned following the transaction, subject to the vesting schedule specified in the award’s footnote disclosure.

What is the exercise price of Elaine K. Sorg’s ARTV Director Stock Option grant?

The Director Stock Option granted to Elaine K. Sorg carries a transaction price per share of $0.0000. This indicates the award was issued as part of director compensation, rather than acquired through an open-market purchase at a prevailing trading price.

How does the vesting schedule work for Elaine K. Sorg’s Artiva Biotherapeutics options?

For this grant, one-third of the shares vested following the grant date. The remaining shares vest monthly over an additional two years following February 18, 2026, creating a multi-year vesting period that ties the director’s potential benefit to continued service and company performance.

Is Elaine K. Sorg’s ownership in Artiva Biotherapeutics direct or indirect?

The filing classifies Elaine K. Sorg’s ownership of the Director Stock Option as direct, indicated by the ownership code "D". No footnote states that another entity holds voting or investment power, so the award is attributed directly to the reporting person herself.